Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy.

Nelson RE, Hoop R, Korner E, DuVall S, Hayden CL, Knippenberg K, Morgan T, Pandya P, Han J, LaFleur J.

Ann Pharmacother. 2014 Jul;48(7):826-836.

PMID:
24760408
2.

High rates of early treatment discontinuation in hepatitis C-infected US veterans.

LaFleur J, Hoop R, Morgan T, DuVall SL, Pandya P, Korner E, Knippenberg K, Hayden C, Nelson RE.

BMC Res Notes. 2014 Apr 24;7:266. doi: 10.1186/1756-0500-7-266.

3.

Predictors of Early Discontinuation of Pegylated Interferon for Reasons Other Than Lack of Efficacy in United States Veterans With Chronic Hepatitis C.

LaFleur J, Hoop R, Korner E, DuVall S, Morgan T, Pandya P, Han J, Knippenberg K, Nelson RE.

Gastroenterol Nurs. 2015 Nov-Dec;38(6):417-28. doi: 10.1097/SGA.0000000000000214.

PMID:
26626031
4.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

5.

Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.

Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A.

Dig Dis Sci. 2011 Aug;56(8):2439-48. doi: 10.1007/s10620-011-1746-3.

PMID:
21633833
6.

Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis.

Hare CB, Loveland JJ, Chu A, Morris JA, Gotz V, Klaskala W.

Curr Ther Res Clin Exp. 2005 Sep;66(5):433-50. doi: 10.1016/j.curtheres.2005.10.005.

8.

Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.

Vigani AG, Gonçales ES, Pavan MH, Genari F, Tozzo R, Lazarini MS, Fais V, Feltrin A, Gonçales NS, Gonçales Jr FL.

Braz J Infect Dis. 2012 May-Jun;16(3):232-6.

9.

Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.

Hermos JA, Quach L, Gagnon DR, Weber HC, Altincatal A, Cho K, Lawler EV, Grotzinger KM.

Pharmacoepidemiol Drug Saf. 2014 May;23(5):480-8. doi: 10.1002/pds.3585.

PMID:
24677630
10.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

11.

Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group..

Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659.

12.

Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis.

Wang X, Liu F, Wei F, Ren H, Hu H.

PLoS One. 2014 Jun 25;9(6):e100128. doi: 10.1371/journal.pone.0100128.

13.

Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA.

Enferm Infecc Microbiol Clin. 2013 Aug-Sep;31(7):424-9. doi: 10.1016/j.eimc.2012.12.004.

PMID:
23453582
14.

The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.

Linas BP, Barter DM, Leff JA, DiLorenzo M, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Freedberg KA.

AIDS. 2014 Jan 28;28(3):365-76. doi: 10.1097/QAD.0000000000000093.

15.

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

Gonçales FL Jr, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS.

BMC Infect Dis. 2010 Jul 20;10:212. doi: 10.1186/1471-2334-10-212.

16.

Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.

Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martín-Carbonero L, Rodríguez-Nóvoa S, Santos I, López-Cortes LF, Merino D, Rivero A, Soriano V.

Antivir Ther. 2008;13(3):429-37.

PMID:
18572756
17.

The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.

Dohmen K, Kawano A, Takahashi K, Shigematsu H, Tanaka H, Haruno M, Yanagita K, Ichiki Y, Mori T, Hayashida K, Shimoda S, Ishibashi H, Nomura H.

Hepatogastroenterology. 2013 Nov-Dec;60(128):2034-8.

PMID:
24719946
18.

Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.

Mira JA, García-Rey S, Rivero A, de los Santos-Gil I, López-Cortés LF, Girón-González JA, Téllez F, Márquez M, Merino D, Ríos-Villegas MJ, Macías J, Rivero-Juárez A, Pineda JA.

Clin Infect Dis. 2012 Dec;55(12):1719-26. doi: 10.1093/cid/cis779.

19.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032.

PMID:
23602817
20.

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy.

Sandoughdaran S, Alavian SM, Sharafi H, Behnava B, Salimi S, Mehrnoush L, Karimi Elizee P, Keshvari M.

Hepat Mon. 2015 Jan 13;15(1):e23564. doi: 10.5812/hepatmon.23564.

Items per page

Supplemental Content

Support Center